Editorial: Did Rick Pazdur's big 'no' on Lilly's China-born PD-1 also spell the end for price disruption?

Kyle Blankenship

Eli Lilly has a big decision coming Thursday as an FDA advisory committee considers the merits of PD-1 blocker sintilimab, a drug developed in China …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Editorial: Did Rick Pazdur's big 'no' on Lilly's China-born PD-1 also spell the end for price disruption?

Kyle Blankenship

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Secretive Treeline Biosciences discloses $421M financing in filing

BenevolentAI CEO is out after less than a year on the job

FDA approves AbbVie's 24-hour Parkinson's infusion therapy after two CRLs

House’s prominent China critic Jim McGovern leads opposition to Biosecure Act: ‘I would prefer to go back to the ...

Sage shakes up senior management, slashes pipeline, sheds 33% of staff

Join the GenScript Biotech Global Forum: Unlocking Innovations in Cell and Gene Therapies

Ed­i­to­r­i­al: Did Rick Paz­dur's big 'no' on Lil­ly's Chi­na-born PD-1 al­so spell the end for price dis­rup­tion?

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Editorial: Did Rick Pazdur's big 'no' on Lilly's China-born PD-1 also spell the end for price disruption?